Questioning Future Growth, Sales
However, Barbara Gilmore, transformational health senior industry consultant at Frost Sullivan, doubts the additional investment will catapult cannabis-based drugs into a large pharmaceutical sales category soon.
“It is unlikely that cannabis-based drugs will grow into a major sub-segment of any market in the foreseeable future,” Gilmore said.
Gilmore cited Evaluate Pharma forecasts showing that among four cannabinoid-based drugs approved in the U.S., or expected to be, only Epidiolex will achieve billion-dollar “blockbuster” annual sales by 2021. That year, Evaluate projects $1.04 billion for Epidiolex—compared with just $52 million in